Items Tagged ‘activin receptor–like kinase 1 (ALK1) signaling inhibitor renal cell carcinoma (RCC)’

March 1st, 2017

Dalantercept- Inlyta Shows Promise for Renal Cell Cancer

By

The combination of Inlyta (axitinib) and dalantercept, an activin receptor–like kinase 1 (ALK1) signaling inhibitor appears promising in the treatment of advanced renal cell carcinoma (RCC) according to the results of a recently published Phase I clinical trial.1 According to investigators, 25% of RCC patients responded to treatment with the combination and this represents an […]

View full entry

Tags: activin receptor–like kinase 1 (ALK1) signaling inhibitor renal cell carcinoma (RCC), dalantercept, News, Renal Cancer